Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production

Taruselli, Marcela T.; Kolawole, Elizabeth Motunrayo; Qayum, Amina Abdul; Haque, Tamara T.; Caslin, Heather L.; Abebayehu, Daniel; Kee, Sydney Ann; Dailey, Jordan; Jackson, Kasey L.; Burchett, Jason; Spence, Andrew J.; Pondicherry, Neha; Barnstein, Brian; Gomez, Gregorio; Straus, David B.; Ryan, John

doi:10.1016/j.cellimm.2021.104457

Cited by 5 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous studies have found that mast cells can exhibit a pro-tumor phenotype during the intermediate and advanced stages of GC, and that this is an independent and unfavorable prognostic factor for GC patients [13] . IL-33 induced mast cell activation can be dependent or independent of IgE/antigen–FcɛRI signals, such as prostaglandins, histamine, chemokines, IL-1β, IL-6, IL-13 and TNF-α [43] , [44] . Our present study found significantly raised IL-2 production by mast cells following stimulation by GC derived-IL-33.…”

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression

Tian

Teng³

et al. 2024

Journal of Advanced Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression

Tian

Teng³

et al. 2024

Journal of Advanced Research

View full text Add to dashboard Cite

“…Natural killer cells treated with statins and IL-2 have shown increased production of cytokines with cytotoxic effects on tumour cells [ 34 ]. Fluvastatin has been shown to simulate IL-33-mediated mast cell activation increasing tumor necrosis factor and IL-6 production [ 35 ]. Indeed, the variation in preclinical studies taken together with conflicting clinical evidence on the association between statins and RA indicates that individual patient characteristics, the type, duration, and intensity of statin use could be important factors affecting the relationship.…”

Section: Discussionmentioning

confidence: 99%

Does the use of statins alter the risk of rheumatoid arthritis? A systematic review and meta-analysis

Pan,

Yang,

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective Statins have anti-inflammatory and immune-modulatory effects which could alter the risk of rheumatoid arthritis (RA). We reviewed published literature and conducted a meta-analysis to examine if statins have an impact on the risk of RA. Methods Case-control studies, cohort studies, or randomized controlled trials (RCT) published on the PubMed, Scopus, and EMBASE databases up to 30th October 2023 were searched. The association between statin use and risk of RA was pooled in a random-effects meta-analysis. Results Nine studies (four cohort, four case-control, and one RCT) were included. Overall, the analysis failed to note an association between the use of statins and the risk of RA with the pooled OR being 0.93 (95% CI 0.82, 1.06). High heterogeneity was noted with I2 = 75%. Results were consistent across study types with no association noted between prior statin use and risk of RA in case-control studies (OR: 0.88 95% CI: 0.69, 1.13), cohort studies (OR: 1.01 95% CI: 0.92, 1.10), and the lone RCT (OR: 1.40 95% CI: 0.50, 3.92). Conclusion Current literature shows that there is no association between the use of statins and the risk of RA. Further rigorous studies taking into account patient factors, duration of statin exposure, and other confounders are needed to generate better evidence.

show abstract

Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation

Zeng,

Wu,

Xiong

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production

Cited by 5 publications

References 69 publications

Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression

Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression

Does the use of statins alter the risk of rheumatoid arthritis? A systematic review and meta-analysis

Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation

Contact Info

Product

Resources

About